NEW YORK CITY, NY / ACCESSWIRE / September 26, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP). Investors who purchased Medpace securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/MEDP.
Investigation Details
On September 25, 2025, Jefferies downgraded Medpace, citing perceived weaknesses in the Company’s business model as a contract research organization amid pressure on biotechnology funding. On this news, Medpace’s stock price fell $35.24 per share, or 9.9%, to close at $320.58 per share on September 25, 2024.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Medpace securities, you can assist this investigation by visiting the firm’s site: bgandg.com/MEDP. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View the original press release on accesswire.com
COMTEX_458204185/2457/2024-09-26T15:01:07